Leeds Teaching Hospitals NHS Trust have announced the signing of a multi-year strategic partnership with Arcturis, the UK leader in the curation of deep, multi-modal data to support the development of precision medicines. This agreement sees the Trust becoming part of Arcturis’ Real-World Data Network (“RWD Network”) that provides comprehensive, real-time access to diverse and enriched health data that is geographical representative of the UK population.
This partnership will bring Leeds Teaching Hospitals clinical expertise and specialism across a range of therapeutic areas including cardiology, neurology and oncology into the Arcturis RWD Network.
Alex Snow, Chief Executive Officer of Arcturis commented, “We are delighted to have partnered with Leeds Teaching Hospitals, a leading acute hospital trust with an outstanding reputation for clinical care, research and innovation across a range of therapeutic areas including oncology. We look forward to working with the team at Leeds to provide precision, regulatory-grade data insights that can be used to enhance the adoption of innovative new therapies and provide better outcomes for patients.”
Dr Paul Jones, Chief Digital Information Officer at Leeds Teaching Hospitals NHS Trust added, “We are excited to partner with Arcturis in this innovative endeavour. By combining our clinical expertise with Arcturis’ data science and analytic capabilities, this partnership has the opportunity to accelerate the development of new therapies and improve patient outcomes.”
The Arcturis RWD Network has been approved by the NHS ethics body, the Health Research Authority, and is designed to curate diverse types of real-world data including medications, laboratory tests, pathology reports, clinical notes and unstructured data into standardised, disease specific datasets. These highly enriched datasets are then used to generate precision data insights that support activities across the drug development pathway including clinical trials, regulatory submissions and post authorisation safety studies.
All insights generated use anonymised patient data and is done to the highest ethical and governance standards to facilitate valuable research and innovation whilst safeguarding the confidentiality and privacy of patients.